Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.
Agilent Technologies is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward advancing the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. By partnering with Agilent for your CDx development, your drug development program will reap the benefits of an innovative industry leader with more than 20 years’ experience. Agilent launched the first FDA-approved companion diagnostic and continues to deliver world-class CDx products in close collaboration with our pharma partners.
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited.
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the naica® system.
Taking advantage of cutting-edge microfluidic innovations, Stilla® aims to make dPCR a lab commodity in all Life Sciences areas: research, therapeutics, and all the “omics”. Learn more about Stilla Technologies:
Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios.
Bio-Techne Companion Diagnostics delivers precision medicine services spanning the continuum from biomarker discovery to post-market commercialization of a CDx product. We bring a 20+ year track record of success including the development of over 2700 assays for 570 targets, with over 50 clinical tests built for pharma and 15 CLIA tests. Our multi-omic, platform-agnostic approach, paired with clinical trial sample testing readiness at our CLIA labs and international regulatory expertise, allows us to offer customizable solutions so that a pharma partner can deliver novel treatments to the patients most likely to benefit, faster.
Biodesix, Inc. is a leading multi-omic diagnostics company providing biopharma services inclusive of biomarker discovery, assay design/development, clinical trial support (sample collection and testing), and companion diagnostic partnering, alongside a portfolio of five on-market clinical diagnostic tests. The company employs genomics, proteomics, and AI to uncover biological information for drug developers.
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and noninvasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX AR-V7 Nucleus Detect test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer.
Labcorp Oncology is committed to advancing cancer care by pioneering scientific breakthroughs, powering better decisions through actionable data-driven patient insights and bringing healthcare within reach for all cancer patients throughout their continuum of care. With our comprehensive, specialized diagnostic services and our drug development capabilities, Labcorp is uniquely positioned to support you, from discovery through post-marketing and commercialization—using a biomarker-driven strategy throughout the entire process. Learn more at: www.oncology.labcorp.com
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA with high accuracy in identifying MRD and predicting recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types. The test is available for clinical and research use, has been designated by the FDA as a Breakthrough Device, received CE mark. Look deeper at:
NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary molecular technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe has sites in Houston, USA, Shanghai, China and Suzhou, China. NuProbe’s vision is to offer affordable, timely, and accurate disease state information to enable precision medicine and improve patient outcomes.
GRAIL is a healthcare company in pursuit of innovation to solve medicine’s most important challenges. Our team of leading scientists, engineers, and clinicians are on an urgent mission to detect more cancers early, when they are more treatable and potentially curable.
Our team brings together biopharma and companion diagnostics expertise with biomarker, drug-diagnostic co-development, and commercialization experience.Data from GRAIL studies have demonstrated analytically validated performance, and robust analytical sensitivity, specificity, and precision.We leverage the combination of GRAIL’s unique methylation-based liquid biopsy platform and biologically motivated machine learning capabilities.
We aim to help our partners accelerate precision oncology across cancer indications and therapeutic modalities with research to clinical trials and, ultimately, registration and commercial launch.
ANGLE’s mission is to enable personalized cancer care by providing the best sample of the patient’s cancer from a simple blood test. ANGLE provides a product-based solution for simple, effective, affordable repeat testing of intact cells.
Cancer Research and Biostatistics
CRAB is a premier oncology research organization with decades of experience in clinical trials in both hematological cancers and solid tumors and related research.
CRAB’s deep oncology expertise and knowledge will provide you with study data and results that are reliable and defensible. CRAB biostatisticians are a renowned group of MS and PhD statisticians skilled in designing clinical studies and analyzing cancer related data. Combined with a customizable electronic data capture system and experienced data management professionals, our dedicated team of subject-matter experts enables seamless clinical trial management and study analysis.
Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases. Our global laboratories, based in the UK and US offer tailored solutions from discovery to commercialisation: Biomarker discovery. Custom assay development & validation. DNA and RNA panel solutions. Flexible CDx development & commercialisation. Expert regulatory support. Bioinformatics & software development. Your Clinical Trial Diagnostic Partner.
Tethis S.p.A., a diagnostic company based in Milan (Italy), aims to enable the exploitation of liquid biopsy multi-biomarkers analysis in clinical practice for precise cancer management by leveraging its expertise in sample preparation and processing. Introducing automation and standardization in the critical pre-analytical phase, Tethis provides the highest quality and integrity of liquid biopsy specimens (plasma and cellular fraction). Processing fresh blood in EDTA at the point of blood collection, it ensures the preservation of all clinically relevant information. The company’s proprietary slides – Smart Bio Surface (SBS), thanks to their functionalized nanocoated surface, allow the spontaneous, immediate, and gentle adhesion of normally non-adherent cells, such as white blood cells (WBCs), with no chemicals, no special temperatures, no other treatment. WBCs adhere to SBS slides as a monolayer distributed on their whole active area. SBS slides, combined with the proprietary automated pre-analytical instrument See.d, allow to identify and characterize rare cells in blood, like CTCs, with unprecedented sensitivity, also in early-stage settings. See.d prepares in a completely automated and gentle manner SBS slides with fixed WBCs as well as tubes with stabilized plasma without specialized operators nor preservatives: both contents are stable and can be easily stored for efficient logistics (i.e., internal analysis or shipment to central lab). Tethis technology makes both CTCs and cell-free content available for biomarkers detection from the same blood draw, enabling multi-omics applications.
Burning Rock Dx specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. With the unique capability and experience in global trials, we are looking for partnerships to advance the field of companion diagnostics in order to achieve better patient outcomes.
In Proud Partnership with:
Friends of Cancer Research is a non-profit that unites scientists, pharmaceutical companies, and policy makers with shared trust and guides them toward meaningful cooperation. We work for patients, families, and anyone impacted by cancer. We drive collaboration from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments to patients.
Friends of Cancer Research is committed to creating and implementing policies ensuring patients receive the best treatments in the fastest and safest way possible.